These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28947651)

  • 1. The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies.
    Wang-Lin SX; Olson R; Beanan JM; MacDonald U; Balthasar JP; Russo TA
    Infect Immun; 2017 Dec; 85(12):. PubMed ID: 28947651
    [No Abstract]   [Full Text] [Related]  

  • 2. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.
    Russo TA; Beanan JM; Olson R; MacDonald U; Cox AD; St Michael F; Vinogradov EV; Spellberg B; Luke-Marshall NR; Campagnari AA
    Infect Immun; 2013 Mar; 81(3):915-22. PubMed ID: 23297385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation the reactivity of a peptide-based monoclonal antibody derived from OmpA with drug resistant pulsotypes of Acinetobacter baumannii as a potential therapeutic approach.
    Yeganeh O; Shabani M; Pakzad P; Mosaffa N; Hashemi A
    Ann Clin Microbiol Antimicrob; 2022 Jun; 21(1):30. PubMed ID: 35773688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production and characterization of novel monoclonal antibodies against outer membrane protein A (OmpA) of Acinetobacter baumannii.
    Yeganeh O; Shabani M; Pakzad P; Mosaffa N; Hashemi A
    J Immunol Methods; 2021 Dec; 499():113169. PubMed ID: 34666009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection.
    Luo G; Lin L; Ibrahim AS; Baquir B; Pantapalangkoor P; Bonomo RA; Doi Y; Adams MD; Russo TA; Spellberg B
    PLoS One; 2012; 7(1):e29446. PubMed ID: 22253723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OmpW is a potential target for eliciting protective immunity against Acinetobacter baumannii infections.
    Huang W; Wang S; Yao Y; Xia Y; Yang X; Long Q; Sun W; Liu C; Li Y; Ma Y
    Vaccine; 2015 Aug; 33(36):4479-85. PubMed ID: 26207591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunization with purified OmpA elicited protective immunity against infections caused by multidrug-resistant Acinetobacter baumannii.
    Zhang X; Yang T; Cao J; Sun J; Dai W; Zhang L
    Microb Pathog; 2016 Jul; 96():20-5. PubMed ID: 27133268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluationof the New Outer Membrane Protein A Epitope-based Vaccines for Mice Model of Acinetobacter baumannii Associated Pneumonia and Sepsis Infection.
    Mehdinejadiani K; Hashemi A; Bandehpour M; Rahmani H; Ranjbar MM; Yardel V; Jalali SA; Mosaffa N
    Iran J Allergy Asthma Immunol; 2021 Sep; 20(5):537-549. PubMed ID: 34664813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor.
    Russo TA; Luke NR; Beanan JM; Olson R; Sauberan SL; MacDonald U; Schultz LW; Umland TC; Campagnari AA
    Infect Immun; 2010 Sep; 78(9):3993-4000. PubMed ID: 20643860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii.
    Huang W; Yao Y; Wang S; Xia Y; Yang X; Long Q; Sun W; Liu C; Li Y; Chu X; Bai H; Yao Y; Ma Y
    Sci Rep; 2016 Feb; 6():20724. PubMed ID: 26853590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A medically relevant capsular polysaccharide in Acinetobacter baumannii is a potential vaccine candidate.
    Yang FL; Lou TC; Kuo SC; Wu WL; Chern J; Lee YT; Chen ST; Zou W; Lin NT; Wu SH
    Vaccine; 2017 Mar; 35(10):1440-1447. PubMed ID: 28190743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First steps towards a vaccine against Acinetobacter baumannii.
    Garcia-Quintanilla M; Pulido MR; McConnell MJ
    Curr Pharm Biotechnol; 2013; 14(10):897-902. PubMed ID: 24372252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal Antibody Therapy against
    Nielsen TB; Yan J; Slarve M; Lu P; Li R; Ruiz J; Lee B; Burk E; Talyansky Y; Oelschlaeger P; Hurth K; Win W; Luna BM; Bonomo RA; Spellberg B
    Infect Immun; 2021 Sep; 89(10):e0016221. PubMed ID: 34310884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoprotective potential of in silico predicted Acinetobacter baumannii outer membrane nuclease, NucAb.
    Garg N; Singh R; Shukla G; Capalash N; Sharma P
    Int J Med Microbiol; 2016 Jan; 306(1):1-9. PubMed ID: 26614015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection.
    Uppuluri P; Lin L; Alqarihi A; Luo G; Youssef EG; Alkhazraji S; Yount NY; Ibrahim BA; Bolaris MA; Edwards JE; Swidergall M; Filler SG; Yeaman MR; Ibrahim AS
    PLoS Pathog; 2018 May; 14(5):e1007056. PubMed ID: 29746596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoprotective potential of BamA, the outer membrane protein assembly factor, against MDR Acinetobacter baumannii.
    Singh R; Capalash N; Sharma P
    Sci Rep; 2017 Sep; 7(1):12411. PubMed ID: 28963492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outer membrane protein A (OmpA) as a potential therapeutic target for Acinetobacter baumannii infection.
    Nie D; Hu Y; Chen Z; Li M; Hou Z; Luo X; Mao X; Xue X
    J Biomed Sci; 2020 Jan; 27(1):26. PubMed ID: 31954394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-reactivity and immunotherapeutic potential of BamA recombinant protein from Acinetobacter baumannii.
    Vieira de Araujo AE; Conde LV; da Silva Junior HC; de Almeida Machado L; Lara FA; Chapeaurouge A; Pauer H; Pires Hardoim CC; Martha Antunes LC; D'Alincourt Carvalho-Assef AP; Moreno Senna JP
    Microbes Infect; 2021; 23(4-5):104801. PubMed ID: 33582283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific egg yolk antibodies (IgY) confer protection against Acinetobacter baumannii in a murine pneumonia model.
    Jahangiri A; Owlia P; Rasooli I; Salimian J; Derakhshanifar E; Naghipour Erami A; Darzi Eslam E; Darvish Alipour Astaneh S
    J Appl Microbiol; 2019 Feb; 126(2):624-632. PubMed ID: 30353977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections.
    Bentancor LV; Routray A; Bozkurt-Guzel C; Camacho-Peiro A; Pier GB; Maira-Litrán T
    Infect Immun; 2012 Oct; 80(10):3381-8. PubMed ID: 22825448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.